A decision-making tool for first-line treatment in advanced non-small-cell lung cancer based on plasma proteome biomarkers

被引：0
|
作者：
Sela, Itamar
Christopoulos, Petros
Puzanov, Igor
Bar, Jair
Zer, Alona
Moskovitz, Mor
Reinmuth, Niels
Lotem, Michal
Katzenelson, Rivka
Agbarya, Abed
Farrugia, David
Price, Gillian
Cheley, Helen
Abu-Amana, Mahmud
McGregor, Kimberly
Lou, Yanyan
Leibowitz, Raya
Dicker, Adam P.
Carbone, David Paul
Gandara, David R.
机构：
[1] OncoHost LTD, Binyamina, Israel
[2] Heidelberg Univ Hosp, Heidelberg, Germany
[3] Roswell Pk Canc Inst, Buffalo, NY USA
[4] Sheba Med Ctr, Ramat Gan, Israel
[5] Rambam Hlth, Haifa, Israel
[6] Davidoff Canc Ctr, Rabin Med Ctr, Beilinson Campus, Petah Tiqwa, Israel
[7] Asklepios Clin Munich Gauting, Thorac Oncol, Gauting, Germany
[8] Hadassah Med Ctr, Jerusalem, Israel
[9] Kaplan Med Ctr, Dept Oncol, Rehovot, Israel
[10] Bnei Tzion Hosp, Haifa, Israel
[11] Gloucestershire Oncol Ctr, Cheltenham, England
[12] NHS Grampian, Aberdeen, Scotland
[13] Swansea Bay UHB, Swansea Bay, Wales
[14] Haemek Med Ctr, Afula, Israel
[15] OncoCyte, Cambridge, MA USA
[16] Mayo Clin, Jacksonville, FL USA
[17] Shamir Med Ctr, Beer Yaagov, Israel
[18] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA USA
[19] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA
[20] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9122
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Penpulimab in combination with anlotinib as first-line treatment in advanced nonsquamous non-small-cell lung cancer.
    Han, Baohui
    Chen, Jianhua
    Wang, Ziping
    Li, Xingya
    Wang, Lin
    Wu, Lin
    Xie, Qiang
    Zhao, Yanqiu
    Wang, Mengzhao
    Lu, Junguo
    Shi, Huaqiu
    Ye, Feng
    Mei, Xiaodong
    Yao, Weirong
    Yue, Lu
    Jiang, Da
    Zhao, Jian
    Zhang, Shucai
    Chen, Gongyan
    Jiao, Shunchang
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
    Ramalingam, Suresh S.
    Yang, James C-H
    Lee, Chee Khoon
    Kurata, Takayasu
    Kim, Dong-Wan
    John, Thomas
    Nogami, Naoyuki
    Ohe, Yuichiro
    Mann, Helen
    Rukazenkov, Yuri
    Ghiorghiu, Serban
    Stetson, Daniel
    Markovets, Aleksandra
    Barrett, J. Carl
    Thress, Kenneth S.
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (09) : 841 - +
  • [23] Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of Outcomes
    Tibaldi, Carmelo
    Mazzoni, Francesca
    Scotti, Vieri
    Vasile, Enrico
    Pozzessere, Daniele
    Stasi, Irene
    Camerini, Andrea
    Federici, Francesca
    Meoni, Giulia
    Caparello, Chiara
    Turrini, Marianna
    Rossi, Virginia
    Ciccone, Lucia Pia
    Pecora, Irene
    Fantechi, Beatrice
    Antonuzzo, Lorenzo
    Giannarelli, Diana
    Baldini, Editta
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2022, 22 (07) : 1278 - 1285
  • [24] Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer
    Sugawara, S.
    Lee, J-S
    Kang, J-H
    Kim, H. R.
    Inui, N.
    Hida, T.
    Lee, K. H.
    Yoshida, T.
    Tanaka, H.
    Yang, C-T
    Nishio, M.
    Ohe, Y.
    Tamura, T.
    Yamamoto, N.
    Yu, C-J
    Akamatsu, H.
    Namba, Y.
    Sumiyoshi, N.
    Nakagawa, K.
    ANNALS OF ONCOLOGY, 2021, 32 (09) : 1137 - 1147
  • [25] Necitumumab for first-line treatment of advanced, squamous, non-small-cell lung cancer: a relevant step forward?
    Zugazagoitia, Jon
    Ponce, Santiago
    Paz-Ares, Luis
    TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (01) : 95 - 97
  • [26] First-line lorlatinib for advanced ALK-positive non-small-cell lung cancer
    Lin, Jessica J.
    Gainor, Justin F.
    LANCET RESPIRATORY MEDICINE, 2023, 11 (04): : 302 - 304
  • [27] Topotecan active as first-line combination therapy for advanced non-small-cell lung cancer
    不详
    ONCOLOGY-NEW YORK, 2001, 15 (02): : 186 - +
  • [28] Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer
    Hayashi, H.
    Okamoto, I.
    Morita, S.
    Taguri, M.
    Nakagawa, K.
    ANNALS OF ONCOLOGY, 2012, 23 (06) : 1537 - 1541
  • [29] Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China
    Xiang, Guiyuan
    Gu, Lingna
    Chen, Xuan
    Wang, Fan
    Chen, Bohua
    Zhao, Jie
    Lu, Yun
    Chang, Feng
    Zhu, Yumei
    FRONTIERS IN PUBLIC HEALTH, 2021, 9
  • [30] Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
    Rizvi, Naiyer A.
    Hellmann, Matthew D.
    Brahmer, Julie R.
    Juergens, Rosalyn A.
    Borghaei, Hossein
    Gettinger, Scott
    Chow, Laura Q.
    Gerber, David E.
    Laurie, Scott A.
    Goldman, Jonathan W.
    Shepherd, Frances A.
    Chen, Allen C.
    Shen, Yun
    Nathan, Faith E.
    Harbison, Christopher T.
    Antonia, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) : 2969 - +
12345